You are here

Aimmune

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Pharmaforum

Mon, 12/27/21 - 11:14 am

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Endpoints

Wed, 01/27/21 - 11:29 am

The top 10 largest biopharma M&A deals in 2020

Fierce Pharma

Tue, 01/19/21 - 10:30 am

Bristol-Myers Squibb

Gilead Sciences

Momenta Pharmaceuticals

Principia Biopharma

Asklepios BioPharmaeutical

Aimmune Becomes Point Pharmaceutical Business for Nestlé

BioSpace

Wed, 10/14/20 - 05:47 pm

Gilead rescues biopharma’s takeout scene

EP Vantage

Wed, 10/7/20 - 11:02 am

Gilead Sciences

Momenta Pharmaceuticals

Principia Biopharma

Tizona Therapeutics

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

Endpoints

Tue, 09/15/20 - 11:01 am

Nestle pays $2 billion to secure Aimmune’s allergy treatment

CNBC

Mon, 08/31/20 - 10:54 am

In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions

Endpoints

Tue, 03/17/20 - 12:01 pm

DBV Technologies

What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline

Motley Fool

Wed, 02/5/20 - 10:14 am

DBV Technologies

Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor

Fierce Biotech

Wed, 02/5/20 - 09:58 am

Aimmune wins approval for peanut immunotherapy, charges 10k+

Endpoints

Sat, 02/1/20 - 11:54 pm

FDA decision nears on Aimmune's contested peanut allergy drug

BioPharma Dive

Fri, 01/24/20 - 12:07 pm

DBV Technologies

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Biopharma Dive

Fri, 09/13/19 - 07:05 pm

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Endpoints

Wed, 09/11/19 - 10:27 am

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Endpoints

Mon, 03/25/19 - 12:03 pm

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

Xconomy

Thu, 02/14/19 - 12:08 am

DBV Technologies

Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment

Stat

Tue, 02/20/18 - 09:24 am

clinical trials

Aimmune's peanut allergy drug clears Phase II on the way to a pivotal test

Fierce Biotech

Tue, 03/8/16 - 10:12 am

clinical trials

Aimmune plots a $153M IPO to fund its 'breakthrough' food allergy pill

Fierce Biotech

Wed, 08/5/15 - 08:58 am